About Aditxt, Inc.
https://www.aditxt.comAditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
CEO
Amro A. Albanna
Compensation Summary
(Year 2024)
Salary $500,000
Total Compensation $500,000
Industry Biotechnology
Sector Healthcare
Went public June 30, 2020
Method of going public IPO
Full time employees 26
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-11-03 | Reverse | 1:113 |
| 2025-03-17 | Reverse | 1:250 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $160
Target Low $160
Target Median $160
Target Consensus $160
Market Cap $17984
52w High $5876.00
52w Low $0.70
P/E 0
Volume 173.31K
Outstanding Shares 21.52K
About Aditxt, Inc.
https://www.aditxt.comAditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $748 ▼ | $3.07M ▼ | $-24.05M ▼ | -3.21M% ▼ | $-548.78 ▼ | $-23.96M ▼ |
| Q2-2025 | $1K ▼ | $6.08M ▲ | $-7.26M ▼ | -722.79K% ▼ | $-390.17 ▲ | $-6.07M ▼ |
| Q1-2025 | $1.02K ▼ | $5.61M ▲ | $-5.71M ▼ | -560.93K% ▼ | $-917 ▲ | $-5.53M ▼ |
| Q4-2024 | $3.17K ▼ | $5.58M ▲ | $-5.23M ▲ | -164.62K% ▼ | $-4.55K ▲ | $-5.07M ▼ |
| Q3-2024 | $6.85K | $4.24M | $-6.94M | -101.26K% | $-3.14M | $-4.55M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $163.04K ▼ | $11.8M ▼ | $20.66M ▼ | $-7.73M ▼ |
| Q2-2025 | $323.68K ▼ | $32.69M ▲ | $20.7M ▲ | $12.96M ▼ |
| Q1-2025 | $476.42K ▼ | $31.22M ▼ | $15.46M ▼ | $16.59M ▲ |
| Q4-2024 | $833.03M ▲ | $32.14M ▲ | $23.86M ▼ | $8.87M ▲ |
| Q3-2024 | $328.6K | $29.84M | $25.39M | $4.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-24.45M ▼ | $-2.34M ▲ | $2.42M ▲ | $2.18M ▼ | $-160.64K ▼ | $-2.34M ▲ |
| Q2-2025 | $-7.4M ▼ | $-2.38M ▲ | $-2.42M ▼ | $4.66M ▼ | $-152.74K ▲ | $-2.38M ▲ |
| Q1-2025 | $-5.71M ▼ | $-11.71M ▼ | $0 ▲ | $11.36M ▲ | $-356.62K ▼ | $-11.71M ▼ |
| Q4-2024 | $-5.55M ▲ | $-6.15M ▼ | $-2.74M ▼ | $9.39M ▲ | $504.44K ▲ | $-6.15M ▼ |
| Q3-2024 | $-6.98M | $-2.36M | $-1.26M | $3.86M | $237.37K | $-2.36M |
CEO
Amro A. Albanna
Compensation Summary
(Year 2024)
Salary $500,000
Total Compensation $500,000
Industry Biotechnology
Sector Healthcare
Went public June 30, 2020
Method of going public IPO
Full time employees 26
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-11-03 | Reverse | 1:113 |
| 2025-03-17 | Reverse | 1:250 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $160
Target Low $160
Target Median $160
Target Consensus $160